Tazocin Intervention Study

NCT00478855

Last updated date
Study Location
Peking, , 100730, China
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Bacterial Infections
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- All patients admitted or transferred to the ICU/pulmonary/Infection units

- Patients of either sex, 18 years of age or older Patients who stay in units less than 48 hours will not be enrolled.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Bacterial InfectionsFrench Study In ICU Patients Treated With Tigecycline
NCT00799591
  1. Paris,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Bacterial InfectionsTazocin Intervention Study
NCT00478855
  1. Peking,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Bacterial InfectionsRelative Bioavailability Study Of Two Lincomycin Hydrochloride Hard Gelatinous Capsule
NCT01058824
  1. Campinas, Sao Paulo
  2. Campinas, Sao Paulo
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Bacterial InfectionsStudy Evaluating Zosyn in Hospitalized Patients With Intra-abdominal Infection
NCT00044928
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Tazocin Intervention Study
Official Title  ICMJE Association of Antibiotic Utilization Measures and Control of ESBLs Producing Bacteria
Brief Summary
  1. To determine the value of using piperacillin/tazobactam in reducing the cases of extended spectrum beta lactamases (ESBL) producing E. coli or K. pneumoniae colonization and infection.
  2. To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, both pre-and post-intervention in the selected medical centers.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Condition  ICMJE Bacterial Infections
Intervention  ICMJE Drug: Tazocin (Piperacillin/Tazobactem)
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE
 (submitted: May 24, 2007)
500
Original Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE June 2007
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • All patients admitted or transferred to the ICU/pulmonary/Infection units
  • Patients of either sex, 18 years of age or older Patients who stay in units less than 48 hours will not be enrolled.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE China
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00478855
Other Study ID Numbers  ICMJE 0910X-102105
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Medical MonitorWyeth is now a wholly owned subsidiary of Pfizer
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date December 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP